Get the latest news, insights, and market updates on HOWL (Werewolf Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Th Sep 2, 2025 - $HOWL
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
– WTX-124 Phase 1/1b clinical trial on track for interim data readout in the fourth quarter of 2025, including patients in both the monotherapy and combination expansion arms of cutaneous melanoma and renal cell carcinoma – – Planning to engage with U.S. Food & Drug Administration (FDA) in the second half of 2025 to discuss potential registrational pathways for WTX-124 in advanced or metastatic cutaneous melanoma – – Phase 1b/2 clinical trial of WTX-330 is actively enrolling, with anticipated de Aug 14, 2025 - $HOWL
XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates
XOMA Royalty (XOMA) delivered earnings and revenue surprises of +500.00% and +39.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock? Aug 13, 2025 - $HOWL
Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates
Beyond Air (XAIR) delivered earnings and revenue surprises of -2.00% and -1.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock? Aug 12, 2025 - $HOWL
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates
CorMedix (CRMD) delivered earnings and revenue surprises of +40.00% and +7.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock? Aug 7, 2025 - $HOWL
ReAlta Life Sciences Appoints Ellen Lubman as Chief Business Officer
By Karen Roman ReAlta Life Sciences, Inc. said it designated Ellen Lubman as Chief Business Officer to supervise business development, capital formation and corporate strategy. Ms. Lubman has nearly 25 years of experience across small to large-cap private and public biopharmaceutical companies with a track record in strategic, transactional, and operational roles, the company stated. […] Jul 29, 2025 - $HOWL
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced Randi Isaacs, M.D., Chief Medical Officer, will speak at the upcoming KidneyCAN 7th Annual Kidney Cancer Research Summit taking place Ju Jul 9, 2025 - $HOWL
Werewolf Therapeutics to Participate in the BIO International Convention
WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced Randi Isaacs, M.D., Chief Medical Officer, will participate in a panel discussion at the upcoming BIO International Convention taking pl Jun 12, 2025 - $HOWL
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple